RSS Feed Content – New on the website
The vaccine "Comirnaty®" is currently authorised for people aged 16 and over. The application asks for the authorisation to be extended to include the age group of 12-15-year-olds.
1953 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated
Reporting ADRs: important information for healthcare professionals and vaccinated individuals
Job advertisement | Abteilung Medical Devices Clinical Investigations
Licences in accordance with art. 22 para. 3 of the COVID 19 Ordinance 3
Swissmedic Journal April 2021
Licence holders required to check suppliers more rigorously
Neue Wartezeit für essbares Gewebe: 70 Tage
Job advertisement | Einheit Inspektorate
1485 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated
MU100_00_003d_MB Produkte mit Cannabidiol (CBD) – Überblick und Vollzugshilfe - German version revised; English version will follow
The active substances in "RegN-Cov 2", the COVID-19 medicinal product from Roche Pharma (Switzerland) AG, are now covered by the COVID-19 Ordinance 3 and may be placed on the market following the submission of an authorisation application to Swissmedic.
Job advertisement | Abteilung Marktkontrolle Arzneimittel
Another COVID-19 vaccine under rolling review
Independence, humanity, strength & integration: those are values we focus on in the 3rd issue of the Swissmedic magazine ‘Visible’. Enjoy the read!
From 1 July 2021 only electronic reports will be accepted
New authorisations – Overview 2020
Job advertisement | Abteilung Arzneimittelsicherheit
1174 reports of suspected adverse reactions to COVID-19 vaccines in Switzerland evaluated
Last modification 01.12.2017